HighTower Advisors’s Atossa Therapeutics ATOS Stock Holding History

HighTower Advisors’s Portfolio ATOS Stock Details ATOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,340	Closed	-$15K	–	3643
2023 Q3	$15K	Hold	1,340	–	–	﹤0.01%	3351
2023 Q2	$25K	Hold	1,340	–	–	﹤0.01%	3234
2023 Q1	$15K	Hold	1,340	–	–	﹤0.01%	3169
2022 Q4	$10K	Hold	1,340	–	–	﹤0.01%	3173
2022 Q3	$15K	Hold	1,340	–	–	﹤0.01%	2990
2022 Q2	$20K	Hold	1,340	–	–	﹤0.01%	2994
2022 Q1	$25K	Hold	1,340	–	–	﹤0.01%	3143
2021 Q4	$30K	Hold	1,340	–	–	﹤0.01%	3071
2021 Q3	$65K	Buy	+1,340	New	+$78K	﹤0.01%	2911

Other funds holding ATOS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

HighTower Advisors's ATOS Position: Q4 2023 in Review

HighTower Advisors sold out of Atossa Therapeutics (ATOS) in Q4 2023, closing a stake of 1,340 shares — an estimated $15K sold.

HighTower Advisors first reported a position in ATOS in Q3 2021 and held it in 9 quarters. The position peaked at $65K in Q3 2021. 49 funds tracked by Wall St. Rank hold ATOS as of Q4 2023.

HighTower Advisors reported no remaining Atossa Therapeutics position as of Q4 2023 after selling out during the quarter.
HighTower Advisors sold 1,340 Atossa Therapeutics shares in Q4 2023, an estimated $15K.
HighTower Advisors first reported a position in Atossa Therapeutics in Q3 2021 and held it in 9 quarters.
HighTower Advisors's Atossa Therapeutics position peaked at $65K in Q3 2021.
49 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q4 2023.

Based on HighTower Advisors's 13F filing for Q4 2023, filed 12 Feb 2024.